Mahajan Shweta, Balcioglu Hayri E, Oostvogels Astrid, Dik Willem A, Chan K C Allen, Lo Kwok-Wai, Hui Edwin P, Tsang Anna, Tong Joanna, Lam Wai Kei Jacky, Wong Kenneth, Chan Anthony T C, Ma Brigette B Y, Debets Reno
Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Laboratory of Medical Immunology, Department of Immunology, Erasmus MC, 3015 GD Rotterdam, The Netherlands.
Cancers (Basel). 2023 Mar 21;15(6):1887. doi: 10.3390/cancers15061887.
Radiotherapy (RT) is the standard-of-care for Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC), where the post-RT clearance of plasma EBV DNA is prognostic. Currently, it is not known whether the post-RT clearance of plasma EBV DNA is related to the presence of circulating T-cell subsets. Blood samples from NPC patients were used to assess the frequency of T-cell subsets relating to differentiation, co-signaling and chemotaxis. Patients with undetectable versus detectable plasma EBV DNA levels post-RT were categorized as clearers vs. non-clearers. Clearers had a lower frequency of PD1+CD8+ T cells as well as CXCR3+CD8+ T cells during RT compared to non-clearers. Clearers exclusively showed a temporal increase in chemo-attractant receptors CCR1, 4 and/or 5, expressing CD8+ T cells upon RT. The increase in CCR-expressing CD8+ T cells was accompanied by a drop in naïve CD8+ T cells and an increase in OX40+CD8+ T cells. Upon stratifying these patients based on clinical outcome, the dynamics of CCR-expressing CD8+ T cells were in concordance with the non-recurrence of NPC. In a second cohort, non-recurrence associated with higher quantities of circulating CCL14 and CCL15. Collectively, our findings relate plasma EBV DNA clearance post-RT to T-cell chemotaxis, which requires validation in larger cohorts.
放射治疗(RT)是爱泼斯坦-巴尔病毒(EBV)相关鼻咽癌(NPC)的标准治疗方法,放疗后血浆EBV DNA的清除情况具有预后意义。目前尚不清楚放疗后血浆EBV DNA的清除是否与循环T细胞亚群的存在有关。我们使用NPC患者的血样来评估与分化、共信号传导和趋化性相关的T细胞亚群的频率。放疗后血浆EBV DNA水平不可检测与可检测的患者分别归类为清除者和未清除者。与未清除者相比,清除者在放疗期间PD1+CD8+T细胞以及CXCR3+CD8+T细胞的频率较低。清除者在放疗时仅表现出趋化因子受体CCR1、4和/或5表达的CD8+T细胞随时间增加。表达CCR的CD8+T细胞增加伴随着幼稚CD8+T细胞减少和OX40+CD8+T细胞增加。根据临床结果对这些患者进行分层后,表达CCR的CD8+T细胞的动态变化与NPC的无复发情况一致。在第二个队列中,无复发与循环中CCL14和CCL15的数量增加有关。总体而言,我们的研究结果将放疗后血浆EBV DNA清除与T细胞趋化性联系起来,这需要在更大的队列中进行验证。